The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: A systematic review of direct and indirect evidence

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 251-268

  Bottomley, Julia M ^a   Taylor, Rod S ^b   Ryttov, Jacob ^c  

^a Amygdala Ltd   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c LEO PHARMA A S   (Denmark)

Author keywords

Calcipotriol betamethasone dipropionate gel; Indirect comparison; Investigator Global Assessment; Scalp psoriasis, meta analysis; Total Sign Score

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CAPASAL; CLOBETASOL PROPIONATE; COAL TAR; FLUOCINOLONE ACETONIDE; MINERAL OIL; PLACEBO; SALICYLIC ACID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PSORIASIS; RATING SCALE; REVIEW; SCALP; SCORING SYSTEM; SKIN DISEASE; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; EVIDENCE-BASED PRACTICE; GELS; HUMANS; PSORIASIS; SCALP DERMATOSES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78650356886     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.541022     Document Type: Review

References (56)

1. Schon MP, Boehncke WH. Psoriasis. N Eng J Med 2005;353:1899-1912
2. Van De Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31-6
3. Van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-34
4. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400
5. Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-7
6. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
7. Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7
8. Chan CS, van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Am Acad Dermatol 2009;60:962-71
9. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65
10. Papp K, Berth-Jones, J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereal 2007;21: 1151-60
11. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study. Dermatology 2008;217: 107-13
12. Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomised, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63
13. Van De Kerkhof P, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Br J Dermatol 2009; 160:170-6
14. Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipo-triol scalp solution in the treatment of scalp psoriasis. Br J Dermatol 2009; 161:159-66
15. Tyring S, Appell M, Bibby A, et al. Calcipotriene/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients. J Am Acad Dermatol 2008;58(2 Suppl. 2): AB125
16. Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipro-pionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomised, 8 week, double-blind phase of a clinical trial. Int J Dermatol 2010;49:1328-33
17. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-8
18. Ortonne JP, Ganslandt C, Tan J, et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009;23: 919-26
19. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10:Appendix 2
20. Committee for Medicinal Products for Human Use (CHMP): Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. EMEA, London 18 November 2004. Available at http:// www.emea.europa.eu/pdfs/human/ewp/245402en.pdf [Last accessed 29 March 2010]
21. Nü esch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515
22. NICE Guide to the methods of technology Appraisal (NICE June 2008). Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuide UpdatedJune2008.pdf [Last accessed 29 March 2010]
23. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331: 897-900
24. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997;50:683-91
25. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
27. Affleck AG, Bottomley JM, Auland ME, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:251-68
28. Smith DRW, Bottomley JM. Auland ME, et al. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:239-49
29. Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000;20:65-8
30. Feldman SR, Ravis SM, Fleischer Jr AB, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001;5:386-9
31. Griffiths CE, Finlay AY, Fleming CJ, et al. A randomised, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006;17:90-5
32. Hillström L, Pettersson L, Svensson L. Comparison of betamethasone dipro-pionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp. J Int Med Res 1982;10:419-22
33. Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12% BMV foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: Quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002;15:27-30
34. Monk BE, Mason RBS, Munro CS, et al. An open and single-blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. J Dermatol Treat 1995;6:159-61
35. Andreassi L, Giannetti A, Milani M, et al. Scale Investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003;148:134-8
36. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects QOL: a randomised single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72:407-11
37. Høvding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981;3:61-6
38. Mazzotta A, Esposito M, Carboni I, et al. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat 2007;18:84-7
39. Thaci D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153-6
40. Duweb G, Alhaddar J, Abuhamida M. Caclipotriol solution in scalp psoriasis. Int J Tissue Reaction 2005;27:163-6
41. Ross SD, Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981;28:438-9
42. Sulzberger MB, Obadia J. A modified liquid petrolatum preparation; its use in the management of certain common dermatoses of the scalp. AMA Arch Derm 1956;73:373-5
43. Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983;32:290-6
44. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7
45. Clinical Study Report. Comparative effects of calcipotriol (MC 903) solution (50 mg/ml) and placebo solution (vehicle of MC 903 solution) in the treatment of scalp psoriasis. A multicentre, prospective randomized double-blind vehicle controlled parallel group study. MC 1190 STUDY. 21 December 1992. Data on file. LEO Pharma
46. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-32
47. Curley RK, Vickers Cfh, Norris T, et al. A comparative study of BDP with salicylic acid and BMV for the treatment of steroid-responsive dermatoses of the scalp. J Derm Treat 1990;1:203-6
48. Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000;39:535-8
49. Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17:390-401
50. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomised comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatol Treat 2005; 16:31-6
51. Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3:367-73
52. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-7
53. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131:678-83
54. Clinical Study Report. Calcipotriol scalp solution II in psoriasis. Efficacy and safety of calcipotriol scalp solution II in scalp psoriasis. A multicentre, prospective, randomized, double-blind, vehicle-controlled, comparative study with 3 parallel groups: calcipotriol scalp solution II 50 mg/ml, calcipotriol scalp solution 50 mg/ml and vehicle of scalp solution II. MCW 9603 INT Study. 10 July 2000
55. Barrett C, Lowsen D, Blades KJ. Limited benefit of combined use of tar-based shampoo with 50mg/ml calcipotriol solution in scalp psoriasis. J Dermatol Treat 2005;16:175
56. Klaber MR, McKinnon C. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal) shampoo, and long-term experience. J Dermatol Treat 2000;11:21-8